Literature DB >> 21554361

Frequency of dog erythrocyte antigen 1.1 expression in dogs from Portugal.

Rui R F Ferreira1, Rafael R Gopegui, Augusto J F Matos.   

Abstract

BACKGROUND: Dog erythrocyte antigen (DEA) 1.1 is the antigen considered most responsible for severe hemolysis owing to incompatible blood transfusions in previously sensitized dogs. Few reports describe the frequency of DEA 1.1 expression in European dogs, and there are no reports in dogs from Portugal.
OBJECTIVE: The aims of this study were to identify the frequency of DEA 1.1 expression in Portuguese dogs, to examine the relationship between phenotypic traits and expression of this blood group, and to assess the risk of transfusing blood that is not typed or cross-matched.
METHODS: Expression of DEA 1.1 was determined in 274 dogs using a migration gel test. Weight, sex, breed, and hair length and color were recorded for each dog. Results were analyzed by descriptive statistical analysis, probabilistic analysis, and χ(2)-tests.
RESULTS: Of 274 dogs, 56.9% were DEA 1.1-positive and 43.1% were DEA 1.1-negative. All Boxers, German Shepherds, and Dobermans were DEA 1.1-negative, whereas all Saint Bernards, 88.9% of Golden Retrievers, 88.2% of Rottweilers, and 61.4% of mixed breed dogs were DEA 1.1-positive. A significant relationship between DEA 1.1 expression and phenotypic traits was not found. The probability of sensitization of recipient dogs following first-time transfusion with blood that was not typed or cross-matched was 24.5%; the probability of an acute hemolytic reaction following a second transfusion with blood from any other donor in the absence of pretransfusion compatibility testing was 6%.
CONCLUSION: The frequency of DEA 1.1 expression in dogs in Portugal is high, and there is a potential risk of sensitization following transfusion with blood that is not typed or cross-matched. Breed-related frequencies may help predict DEA 1.1-positivity, but the best practice is to type and cross-match blood before transfusion. ©2011 American Society for Veterinary Clinical Pathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21554361     DOI: 10.1111/j.1939-165X.2011.00311.x

Source DB:  PubMed          Journal:  Vet Clin Pathol        ISSN: 0275-6382            Impact factor:   1.180


  6 in total

1.  Frequency of DEA 1 antigen in 1037 mongrel and PUREBREED dogs in ITALY.

Authors:  E Carli; A Carminato; S Ravagnan; K Capello; M T Antognoni; A Miglio; T Furlanello; D Proverbio; E Spada; A Stefani; F Mutinelli; M Vascellari
Journal:  BMC Vet Res       Date:  2017-11-29       Impact factor: 2.741

2.  Prevalence of Dog Erythrocyte Antigen 1 in 7,414 Dogs in Italy.

Authors:  Anyela Andrea Medina Valentin; Alessandra Gavazza; George Lubas
Journal:  Vet Med Int       Date:  2017-09-24

3.  A study on the prevalence of dog erythrocyte antigen 1.1 and detection of canine Babesia by polymerase chain reaction from apparently healthy dogs in a selected rural community in Zimbabwe.

Authors:  Solomon Dhliwayo; Tariro A Makonese; Belinda Whittall; Silvester M Chikerema; Davies M Pfukenyi; Musavenga T Tivapasi
Journal:  J S Afr Vet Assoc       Date:  2016-10-26       Impact factor: 1.474

Review 4.  Canine Blood Group Prevalence and Geographical Distribution around the World: An Updated Systematic Review.

Authors:  Sara Mangiaterra; Giacomo Rossi; Maria Teresa Antognoni; Matteo Cerquetella; Andrea Marchegiani; Arianna Miglio; Alessandra Gavazza
Journal:  Animals (Basel)       Date:  2021-01-29       Impact factor: 2.752

5.  Prevalence of Dog Erythrocyte Antigens 1, 4, and 7 in Podenco Ibicenco (Ibizan Hounds) from Ibiza Island.

Authors:  Eva Spada; Daniela Proverbio; Luis Miguel Viñals Flórez; Blanca Serra Gómez de la Serna; Maria Del Rosario Perlado Chamizo; Luciana Baggiani; Roberta Perego
Journal:  Vet Med Int       Date:  2016-02-29

6.  The dog erythrocyte antigen 1 blood group in nondomesticated canids and compatibility testing between domestic dog and nondomesticated canid blood.

Authors:  Thomas Charpentier; Thierry Petit; Maryline Guidetti; Isabelle Goy-Thollot
Journal:  J Vet Intern Med       Date:  2020-11-03       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.